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OBJECTIVES: The aim of this study was to investigate the role of the interleukin-18 +105A/C and interleukin-10 -
1082A/G germline polymorphisms in the development and outcome of differentiated thyroid carcinoma associated
or not with concurrent thyroiditis.
METHODS: We studied 346 patients with differentiated thyroid carcinomas, comprising 292 papillary carcinomas
and 54 follicular carcinomas, who were followed up for 12-298 months (mean 76.10¡68.23 months) according to a
standard protocol. We genotyped 200 patients and 144 control individuals for the interleukin-18 +105A/C
polymorphism, and we genotyped 183 patients and 137 controls for the interleukin-10 -1082A/G polymorphism.
RESULTS: Interleukin-18 polymorphisms were not associated with chronic lymphocytic thyroiditis or any clinical or
pathological feature of tumor aggressiveness. However, there was an association between the presence of
interleukin-10 variants and chronic lymphocytic thyroiditis. Chronic lymphocytic thyroiditis was present in 21.74% of
differentiated thyroid carcinoma patients, most frequently affecting women previously diagnosed with Hashimoto’s
thyroiditis who had received a lower 131I cumulative dose and did not present lymph node metastases.
CONCLUSIONS: We conclude that the inheritance of a G allele at the interleukin-10 -1082A/G polymorphism may
favor a concurrent thyroid autoimmunity in differentiated thyroid carcinoma patients, and this autoimmunity may
favor a better prognosis for these patients.
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INTRODUCTION
An association between chronic lymphocytic thyroiditis
(CLT), also known as Hashimoto’s thyroiditis, and differ-
entiated thyroid carcinoma (DTC), especially the papillary
histotype, has long been recognized and supported by a
series of epidemiological studies.1,2 Chronic inflammatory
infiltrates and chronic inflammatory thyroiditis are observed
in 20-50% of papillary thyroid carcinoma (PTC) cases.3,4
Moreover, autoimmune thyroid diseases and DTC share
numerous morphological and molecular traits.5,6 However,
the relationship between autoimmune thyroid diseases and
DTC remains controversial. On the one hand, chronic
inflammation related to Hashimoto’s thyroiditis might
predispose individuals to neoplastic transformation and
cancer development.6 Several cytokines, including interleu-
kin (IL)-1, IL-6 and tumor necrosis factor (which are
produced by tumor cells), and tumor-associated leukocytes
and platelets have been found to contribute to the invasive
phenotype.7 On the other hand, genetic alterations implicated
in PTC, such as RET/PTC, BRAFV600E and RASG12V, have
been demonstrated to help promote a proinflammatory
environment characterized by high levels of proinflamma-
tory cytokines that provide a protumorigenic condition.8
Thyroid cancer cells also secrete several cytokines and
chemokines necessary to sustain cancer cell growth and
recruit leukocytes to tumor sites.7,9
Interleukin-18 has multiple functions, including the induc-
tion of interferon-gamma synthesis by T cells and natural
killer cells,10 the promotion of T-helper (Th) 1-type immune
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responses, the augmentation of the proliferative response,
and activated T-cell cytokine production.11 The IL-18 gene is
located on chromosome 11q22.2-q22.3 and consists of six
exons and five introns. The promoter region of the gene can
harbor nucleotide variations that affect IL-18 synthesis.12 An
IL-18 gene polymorphism at position +105 has been linked
to increased production of this cytokine.13
Interleukin-10 is a pleiotropic cytokine with both anti-
inflammatory and anti-angiogenic properties that may be
involved in the pathogenesis of autoimmune thyroid
diseases.14 It is normally produced by activated T cells,
monocytes, B cells, and thymocytes, contributing to antigen-
or mitogen-driven B cell differentiation, acting as a growth
factor, and stimulating the humoral immune response.15
The IL-10 gene is located on chromosome 1q31-q32. Thyroid
cancer cells of all histological variants produce considerable
amounts of IL-10, which might be important in the
pathological features of thyroid cancer and/or outcome.16
A polymorphism at codon -1082 has been associated with
increased IL-10 protein production.17
The aim of this study was to investigate the roles of the IL-
18 +105A/C and IL-10 -1082A/G germline polymorphisms
in the development and outcome of DTC associated or not
with concurrent thyroiditis.
MATERIALS AND METHODS
Subjects
This retrospective case-control study was approved by
the Research Ethics Committee of the Faculty of Medical
Sciences – University of Campinas (FCM-Unicamp), and
informed written consent was obtained from all individuals.
The study was designed and conducted in accordance with
good clinical practice guidelines, the relevant laws regard-
ing the conduct of clinical studies, and the Declaration of
Helsinki. The study population comprised 346 patients with
DTC (292 PTC cases and 54 follicular carcinoma [FTC]
cases) who underwent surgery between 1999 and 2007 in
Hospital das Clı´nicas – Faculty of Medical Sciences –
Unicamp. Thyroid carcinoma had been either diagnosed
or suspected in these patients for clinical or epidemiological
reasons, including the results of fine-needle aspiration
cytology and/or histological analysis. All of the patients
underwent total or near-total thyroidectomy. Patients with
preoperatively or intraoperatively palpable neck node
metastases underwent regional neck dissection. The stage
and grade of tumor differentiation were obtained from
surgical and pathological records. Experienced pathologists
of the Hospital das Clı´nicas – Faculty of Medical Sciences –
Unicamp confirmed all diagnoses. All the cases were
managed according to a standard protocol. Total body 131I
scans were performed 4-6 weeks after the operations. A total
of 27 patients who were classified as very low-risk – patients
with unifocal microcarcinoma (T1#1 cm, according to the
International Union Against Cancer [AJCC/UICC] staging
system) and no extension beyond the thyroid capsule or
distant metastases (N0M0) – did not receive any actinic dose
after ablation; all other patients received at least 100 mCi of
131I. Long-term levothyroxine therapy at suppressive doses
was administered following total body scans to keep serum
thyrotropin (TSH) at low-normal levels.
Data on lifetime occupational history, dietary habits,
alcohol and drug consumption, medical history with an
emphasis on previous and/or current thyroid diseases,
family history of DTC, and other anamnestic data were
obtained by interviews, using a structured questionnaire.
Individuals with a history of accidental or medical radiation
exposure or other antecedent malignancies were excluded.
Skin color was determined by the interviewer in accordance
with the Brazilian Institute of Geography and Statistics
(http://www.ibge.gov.br/english/); however, due to the
difficulty in classifying our highly heterogeneous popula-
tion, we grouped it into Caucasian and non-Caucasian.
Cigarette smoking habits were recorded; however, due to
the limited reliable data obtained on smoking duration, the
age at which smoking began, the quantity smoked, and the
time elapsed since smoking cessation, the patients were
grouped into never smokers and ever smokers. The latter
group comprised individuals who had consumed at least 20
packs (at 20 cigarettes per pack) for 1 of the prior 5 years. All
data, including nodule size, tumor histological features, and
the results of laboratory examinations, were confirmed by
the patients’ records.
Follow-up
According to a routine protocol based on American
Thyroid Association and Latin American Thyroid Society
recommendations,18,19 the follow-up of cancer patients
included periodic total body scans, serum TSH and
thyroglobulin (Tg) measurements and other eventual
procedures for detecting distant metastases for a period of
1-336 months (76.10¡68.23 months). Patients presenting
with or suspected of high non-stimulated serum Tg levels
(.2 mg/dl) underwent total body scans. We defined tumors
as recurrent and/or presenting long-distance metastasis
according to the above parameters.
According to the total actinic ablation received prior to
this study, the patients were divided into two groups: (a)
patients with cumulative doses bellow 250 mCi and (b)
patients with cumulative doses above 250 mCi.
Controls
We selected 416 healthy controls from the general
population of our region; we considered these individuals
to have a normal iodine intake, and they were matched to
the patients on the basis of gender, age, ethnicity, and
environmental exposure risk. Hence, the 200 DTC patients
genotyped for the IL-18 polymorphism were compared with
144 control individuals, and the 183 patients genotyped for
the IL-10 polymorphism were compared with 137 controls.
The history obtained from these control subjects included
demographic and ethnic background, diet, lifetime occupa-
tional history, smoking and drinking history, general health
conditions, and disease history. Individuals with a history
of thyroid disease, radiation exposure, specific environ-
mental or occupational exposure risks, or antecedent
malignancy were excluded.
Histopathology
Experienced pathologists confirmed the diagnosis of PTC
in 292 patients (159 with the classical form of the disease, 88
with follicular variants, 23 with tall-cell variants, and 22
with less-differentiated variants) and FTC in 54 cases (all
clearly invasive tumors). CLT was investigated in the non-
malignant thyroid parenchyma of all the DTC patients. The
presence of thyroiditis was confirmed by extensive diffuse
lymphocytic infiltration with the formation of lymphoid
follicles or reactive germinal centers and scarring, as well as
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follicular regenerative activity in the form of numerous
small follicles frequently lined by Hurthle cells. The Hurthle
cells had abundant eosinophilic cytoplasm, enlarged hyper-
chromatic nuclei, mildly to moderately pleomorphic nuclei,
and prominent nucleoli. Peritumoral inflammatory response
was not considered chronic lymphocytic thyroiditis.
Identification of Genotypic Profiles
Blood specimens were obtained from patients and
controls. Genomic DNA was extracted from frozen speci-
mens, and leukocytes were separated from whole blood
using a standard proteinase K-phenol-chloroform protocol.
Both the IL-18 (+105A/C) and IL-10 (-1082A/G) genotypes
were analyzed by the polymerase chain reaction (PCR) and
restriction fragment length polymorphism (RFLP) methods.
Genotyping was conducted with blinding to case/control
status. The primers for IL-18 +105A/C were forward 59-
AGA TTT AAT GTT TAT TGT AGA AAA CCT GGA CTC -
39 and reverse 59- CAG TCA TAT CTT CAA ATA GAG
GCC G-39 , which produced a 141-bp fragment. The primers
for IL-10 -1082A/G were forward 59- CTG GCT GCA ACC
CAA CTG GC -39 and reverse 59- TCT TAC CTA TCC CTA
CTT CC -39, which generated a 139-bp fragment. These
fragments were amplified separately under similar condi-
tions in 25-ml volumes of a mixture containing 100 ng of
DNA, 10 mM of each primer, 10 mM Tris-HCl (pH 8.0),
0.1 mM of each dNTP, 2.0 mM MgCl2, and 0.5 U Taq DNA
polymerase. The samples were amplified for 35 cycles at
94 C˚ for 55 sec followed by 72 C˚ for 1 min, with an initial
denaturation step at 94 C˚ for 5 min and a final extension
step at 72 C˚ for 10 min, using a Thermocycler MJ PTC-200
PCR System (Harlow Scientific, Arlington, USA). The PCR
fragments were visualized in ethidium bromide-stained
gels. The DdeI restriction enzyme was used to identify the
IL-18 polymorphism according to the manufacturer’s pro-
tocol (Fermentas, Vilnius, Lithuania). The IL-18 A allele
generated a double band representing 109- and 32-bp
fragments, and the IL-18 C variant allele produced one
fragment of 141 bp. The MnlI restriction enzyme was used
to identify the IL-10 polymorphism according to the
manufacturer’s protocol (Fermentas, Vilnius, Lithuania).
The IL-10 A allele generated a single band representing a
139-bp fragment, and the IL-10 G variant allele produced
two fragments of 106 and 33 bp. The restriction products
were analyzed by electrophoresis in 3% agarose gels
containing ethidium bromide.
Statistical Analysis
Statistical analyses were conducted using SAS statistical
software (Statistical Analysis System, version 8.1, Cary, NC,
USA, 1999-2000). Associations were assessed using 2X2 or
2Xn contingency table analysis; the chi-squared (x2) or
Fisher’s (F) exact test was used to examine homogeneity
between cases and controls in terms of gender, race,
previous thyroid disease, thyroid nodule size, medication
use, cigarette smoking, disease extent, and genotypes. The
Kruskal-Wallis (KW) test was used to compare age among
the groups. The Mann-Whitney or Wilcoxon test was used
to compare age among the different genotype groups. The
observed genotype frequencies were compared with those
calculated using Hardy-Weinberg equilibrium theory. The
95% CI odds ratio (OR) provided a measure of strength of
association. To further explore the significance of the
studied genotypes in different age ranges, we performed a
univariate logistic regression analysis in patients under and
over 45 years old after adjusting for gender. The 23 tall-cell
variant cases and the 22 samples of less-differentiated
variants were excluded from all comparisons concerning
DTC. Logistic regression analysis was used to evaluate the
effects of all genotypes after adjusting for potential
confounders, such as age, gender, race, tobacco use, and
alcohol use. A multivariate logistic regression model was
applied using the presence/absence of CLT as the depen-
dent variable and all genotypes and clinical risk factors,
including gender, age, and cumulative radioiodine doses, as
explicative variables. The Cox regression model was used to
search for associations between risk factors and disease-free
survival in thyroid cancer patients. All tests were conducted
at a 5% significance level (p,0.05).
RESULTS
Table 1 summarizes the demographics, pathological
features, and follow-up characteristics of the 346 patients
with DTC, including the 200 patients genotyped for the IL-
18 +105A/C polymorphism and the 183 patients genotyped
for the IL-10 -1082A/G polymorphism. As expected, the
DTC patients were predominantly female (85%). There were
no differences between the control individuals and the
cancer patients in terms of ethnicity (78.06% Caucasian and
21.94% non-Caucasian versus 82.82% Caucasian and 17.18%
non-Caucasian patients, respectively; p= 0.117) or smoking
habits (70.95% non-smokers and 29.05% smokers versus
72.17% non-smokers and 27.82% smokers, respectively;
p= 0.729). The mean age at the time of diagnosis was
41.62¡14.89 years (range of 5-87 years). According to the
pathologic TNM staging system, 210 (60.58%) patients were
stage I, 84 (24.36%) stage II, 30 (8.65%) stage III, and 22
(6.41%) stage IV. Most DTC cases were classified as
differentiated tumors (88.26%), 42.28% were multicentric,
and 86 (24.85%) presented lymph node metastasis at the
time of diagnosis. Lymph node metastases were more
frequent in patients with multifocal tumors (36.64%) than in
patients with a single tumor focus (19.25%; p= 0.0007).
A total of 24 DTC patients had previously been diagnosed
with autoimmune disease, including eight cases (8 PTC) of
Hashimoto’s thyroiditis and 16 cases (14 PTC and 2 FTC) of
Basedow-Graves’ disease.
The IL-18 and IL-10 genotype profiles were according to a
Hardy-Weinberg equilibrium (IL-18: x2 = 0.210, gl = 2,
p= 0.900; IL-10: x2 = 1.616, gl = 2, p= 0.445). We were unable
to find any differences in IL-18 or IL-10 genotype distribu-
tion between the controls and patients (p= 0.342 and
p= 0.665, respectively). Further investigation into possible
associations among IL-18 and IL-10 polymorphism profiles,
tumor features, and patient outcomes, as shown in Table 1,
did not reveal any association between genotype and
aggressive clinical characteristics at diagnosis or during
follow-up. Moreover, there was no relationship between IL-
18 or IL-10 genotype and previous diagnosis of autoimmune
disease. There were no differences in IL-18 polymorphism
profiles between patients with or without CLT. However, a
multivariate regression analysis showed that CLT was more
frequent in patients with the IL-10 variant allele than in
patients with the wild-type AA genotype (p= 0.039).
Whereas CLT was present in 21.41% of the DTC samples,
257 (78.59%) patients did not present with CLT, and
histological characteristics were ambiguous in the remaining
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Table 1 - Demographics, pathological features and follow-up characteristics of the differentiated thyroid cancer
patients according to their genotypic distribution of interleukin-18 +105A/C (IL-18 +105A/C) and interleukin-10 -1082A/
G (IL-10 -1082A/G) polymorphic profiles. PTC= papillary thyroid carcinoma; N= absolute number of patients; pTNM=
International Union Against Cancer (AJCC/UICC) staging system.
Demographic/Pathological/
Follow-up Factors IL-18 genotype IL-10 genotype
AA AC CC AA AG GG
N (%) N (%) N (%) p-value N (%) N (%) N (%) p-value
Gender
Female 69 (42.86) 75 (46.58) 17 (10.56) 0.279 63 (42.86) 61 (41.50) 23 (15.64) 0.330
Male 9 (28.12) 18 (56.25) 5 (15.63) 10 (32.26) 13 (41.93) 8 (25.81)
Ethnicity
White 77 (40.96) 90 (47.87) 21 (11.17) 0.684 54 (38.57) 60 (42.86) 26 (18.57) 0.453
Non-white 17 (44.74) 16 (42.10) 5 (13.16) 18 (50.00) 13 (36.11) 5 (13.89)
Smoking
Smoker 21 (35.00) 33 (55.00) 6 (10.00) 0.435 23 (41.81) 21 (38.18) 11 (20.01) 0.694
Non-smoker 56 (43.41) 58 (44.96) 15 (11.63) 48 (40.00) 53 (44.17) 19 (15.83)
Age
,40 33 (39.29) 43 (51.90) 8 (8.81) 0.745 35 (45.45) 32 (41.56) 10 (12.99) 0.336
$40 45 (40.90) 51 (46.36) 14 (12.74) 38 (37.62) 42 (41.58) 21 (20.80)
Tumor Type
Papillary (PTC) 62 (38.99) 80 (50.31) 17 (10.70) 0.429 62 (40.00) 67 (43.23) 26 (16.77) 0.504
Follicular (FTC) 16 (47.06) 13 (38.23) 5 (14.71) 11 (47.83) 7 (30.43) 5 (21.74)
PTC histological variants
Classical 33 (38.82) 43 (50.58) 9 (10.60) 0.622 30 (36.14) 40 (48.19) 13 (15.67) 0.409
Follicular 14 (31.81) 23 (52.27) 7 (15.92) 22 (51.16) 14 (32.56) 7 (16.28)
Others 25 (46.29) 23 (42.59) 6 (11.12) 19 (40.42) 18 (38.30) 10 (21.28)
Concurrent thyroiditis
Yes 18 (40.90) 24 (54.54) 2 (4.56) 0.241 13 (31.71) 22 (53.66) 6 (14.63) 0.208
No 57 (39.04) 69 (47.26) 20 (13.70) 60 (44.12) 52 (38.23) 24 (17.65)
Multifocality
Multinodular 26 (37.68) 36 (52.17) 7 (10.15) 0.740 30 (46.15) 27 (41.54) 8 (12.31) 0.447
Uninodular 46 (40.00) 54 (46.95) 15 (13.05) 41 (38.68) 45 (42.45) 20 (18.87)
Extrathyroidal invasion
Yes 33 (37.50) 47 (53.41) 8 (9.09) 0.527 31 (39.24) 34 (43.04) 14 (17.72) 0.725
No 39 (41.49) 43 (45.74) 12 (12.77) 40 (44.94) 36 (40.45) 13 (14.61)
pTNM stage
I 43 (41.35) 51 (49.04) 10 (9.61) 0.653 44 (44.90) 39 (39.80) 15 (15.30) 0.705
II 19 (39.58) 22 (45.83) 7 (14.59) 15 (34.09) 20 (45.45) 9 (20.46)
III 6 (27.27) 12 (54.54) 4 (18.19) 9 (42.86) 8 (38.09) 4 (19.05)
IV 5 (41.66) 7 (58.34) 0 (0.00) 2 (22.22) 6 (66.67) 1 (11.11)
Microcarcinoma
Yes 23 (48.93) 19 (40.42) 5 (10.65) 0.230 20 (43.48) 18 (39.13) 8 (17.44) 0.946
No 49 (35.00) 74 (52.86) 17 (12.14) 53 (41.08) 54 (41.86) 22 (17.06)
Differentiation grade
Well differentiated 64 (40.76) 72 (45.86) 21 (13.38) 0.128 64 (43.84) 57 (39.04) 25 (17.12) 0.283
Poorly differentiated 4 (28.57) 10 (71.43) 0 (0.00) 4 (26.67) 9 (60.00) 2 (13.33)
Lymph node metastasis
Yes 16 (31.37) 30 (58.82) 5 (9.80) 0.176 22 (43.14) 23 (45.10) 6 (11.76) 0.485
No 66 (44.59) 65 (43.92) 17 (11.49) 54 (41.22) 52 (39.69) 25 (19.09)
Distant metastasis
Yes 7 (30.43) 15 (65.22) 1 (4.35) 0.171 6 (30.00) 12 (60.00) 2 (10.00) 0.181
No 76 (42.94) 80 (45.20) 21 (11.86) 70 (42.94) 63 (38.65) 30 (18.41)
Familial cases
Yes 2 (40.00) 2 (40.00) 1 (20.00) 0.652 2 (50.00) 2 (50.00) 0 (0.00) 1.000
No 81 (41.54) 93 (47.69) 21 (10.77) 74 (41.34) 73 (40.78) 32 (17.88)
Hashimoto’s thyroiditis
Yes 2 (50.00) 2 (50.00) 0 (0.00) 1.000 2 (50.00) 2 (50.00) 0 (0.00) 1.000
No 73 (39.67) 89 (48.37) 22 (11.96) 71 ( 41.52) 70 (40.94) 30 (17.54)
Basedow-Graves’ disease
Yes 3 (42.86) 3 (42.86) 1 (14.28) 1.000 3 (37.50) 1 (12.50) 4 (50.00) 0.053
No 72 (39.78) 88 (48.62) 21 (11.60) 70 (41.92) 71 (42.51) 26 (15.57)
Metastasis during follow-up
Yes 6 (50.00) 5 (41.67) 1 (8.33) 0.909 7 (53.85) 5 (38.46) 1 (7.69) 0.522
No 77 (40.96) 90 (47.87) 21 (11.17) 69 (40.59) 70 (41.18) 31 (18.23)
Cumulative 131I dose
,250 mCi 16 (41.03) 20 (51.28) 3 (7.69) 0.753 13 (37.14) 16 (45.71) 6 (17.15) 0.353
$250 mCi 10 (32.26) 19 (61.29) 2 (6.45) 15 (50.00) 13 (43.33) 2 (6.67)
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19 cases, which were therefore excluded from further
analysis. We also evaluated the influence of CLT on DTC
presentation and outcome, as shown in Table 2. CLT was
more frequent in women (p= 0.020) previously diagnosed
with Hashimoto’s thyroiditis (p,0.001) and who had
received a lower 131I cumulative dose (p= 0.005). A multi-
variate regression analysis confirmed significant associations
among the presence of CLT, female gender (p= 0.013) and the
absence of lymph node metastasis at diagnosis (p= 0.012).
To further explore the influence of autoimmunity on DTC
prognosis, we grouped all the DTC patients with lympho-
cytic infiltration surrounding neoplastic tissue and/or
circulating autoantibodies and/or preoperative diagnosis
of Graves’ disease or Hashimoto’s thyroiditis. These 89
patients (83 women and 6 men, mean age ¡ SD
41.45¡14.84) were then compared with 239 DTC patients
(198 women and 41 men, mean age ¡ SD 41.62¡14.89)
without any histological or serological evidence of thyroid
autoimmunity. Eighteen patients with ambiguous data were
excluded from further analysis. Again, the presence of
autoimmunity was correlated with female gender
(p= 0.020), absence of lymph node metastasis at diagnosis
(p= 0.017), and lower 131I cumulative dose (p= 0.025).
DISCUSSION
We were unable to find any association between the IL-18
+105A/C polymorphism and DTC with CLT or previous
autoimmune thyroid diseases. Neither the IL-18 nor the IL-
10 genotype was differentially distributed between patients
and controls, indicating that these genotypes are not a risk
factor for DTC development. However, there was an
association between the presence of IL-10 variants and
CLT. In addition, we demonstrated that CLT accompanied
by DTC is associated with good prognostic features,
including female gender, lower 131I cumulative dose, and
absence of lymph node metastasis at diagnosis.
Because IL-10 may be involved in leukocyte recruit-
ment,14,20 and the studied polymorphism increased IL-10
protein levels,17 we could speculate that individuals with
the inherited polymorphic variant would be more efficient
at increasing their IL-10 levels, leading to thyroid auto-
immunity. The IL-10 -1082A/G polymorphism has been
associated with the development of various types of cancer,
including thyroid cancer.21-24 In a recent work, Erdogan and
colleagues21 studied the IL-10 -1082A/G polymorphism in
patients with papillary thyroid carcinoma and control
individuals using the same genotyping technique as in our
study but a smaller cohort. They obtained a genotype profile
similar to that reported here. However, patients with a
heterozygous genotype were more frequent in the Erdogan
cohort (61.9%) than in our cohort (44.53%), which suggests
that the genetic backgrounds of different populations may
influence DTC development.
Although we confirmed a previously reported association
between thyroid autoimmunity and tumor features related
to a good prognosis,3,25-30 this issue is still being debated.
Although a worse prognosis has been reported for patients
with thyroid autoimmunity in a few series,31,32 most studies
have shown either a protective effect3,13,14,27,33 or no effect of
thyroid autoimmunity on DTC behavior.34
Hashimoto’s thyroiditis is characterized by follicular cell
depletion due to an immune system reaction against a series
of thyroid epithelial cell antigens. DTC cells might also be
recognized and destroyed by the immune system, which
would explain why DTC patients with concomitant auto-
immune thyroid diseases may present a better prog-
nosis.25,35 The immune response is modulated by a
complex network of cytokines, and the final output of this
Table 2 - Demographics, pathological features and
follow-up characteristics of 327 differentiated thyroid
carcinoma patients presenting concurrent lymphocytic
thyroiditis (N=70 patients) or not (N=257 patients). The
data were obtained using a multivariate regression
analysis. IL = interleukin; N= absolute number of
patients.
Thyroiditis
Present Absent p-value
Demographic/Pathological/
N (%) N (%)Follow-up Factors
Gender
Female 66 (23.57) 214 (76.43) 0.013
Male 4 (8.51) 43 (91.49)
Ethnicity
White 60 (22.56) 206 (77.44) 0.475
Non-white 10 (18.18) 45 (81.82)
Smoking
smoker 15 (16.67) 75 (83.33) 0.175
non-smoker 55 (23.61) 178 (76.39)
Age
,40 32 (21.48) 117 (78.52) 0.978
$40 38 (21.35) 140 (78.65)
Extrathyroidal invasion
Yes 28 (19.31) 117 (80.69) 0.377
No 38 (23.46) 124 (76.54)
pTNM stage
I 42 (22.46) 145 (77.54) 0.678
II 20 (26.32) 56 (73.68)
III 5 (18.52) 22 (81.48)
IV 3 (15.00) 17 (85.00)
Microcarcinoma
Yes 20 (27.03) 54 (72.97) 0.209
No 50 (20.16) 198 (79.84)
Differentiation grade
Well differentiated 54 (20.61) 208 (79.39) 0.282
Poorly differentiated 10 (28.57) 25 (71.43)
Lymph node metastasis
Yes 12 (14.12) 73 (85.88) 0.012
No 58 (24.17) 182 (75.83)
Distant metastasis
Yes 5 (14.71) 29 (85.29) 0.310
No 65 (22.26) 227 (77.74)
Familial cases of thyroid cancer
Yes 3 (33.33) 6 (66.67) 0.409
No 67 (21.07) 251 (78.93)
Preoperative Hashimoto’s
thyroiditis
Yes 7 (87.5) 1 (12.50) ,0.001
No 63 (20.00) 252 (80.00)
Metastasis during follow-up
Yes 2 (10.00) 18 (90.00) 0.267
No 68 (22.15) 239 (77.85)
Cumulative radioiodine dose
,250 mCi 18 (36.73) 31 (63.27) 0.005
$250 mCi 6 (12.24) 43 (87.76)
IL-10 genotype
AA 13 (17.81) 60 (82.19) 0.039
AG/GG 28 (26.92) 76 (73.08)
IL-18 genotype
AA 18 (24.00) 57 (76.00) 0.969
AC/CC 26 (22.61) 89 (77.39)
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interaction can be either the stimulation or the suppression
of immunity. Therefore, merely analyzing IL-10 and IL-18 is
not sufficient to understand the immune response against
thyroid cancer. More studies are warranted to confirm the
hypothesis of tumor destruction by immune reaction and to
elucidate the mechanisms engaged in this process.
CONCLUSIONS
In conclusion, we suggest that neither the IL-18 +105A/C
nor the IL-10 -1082A/G polymorphisms represent risk
factors for the development or outcome of DTC. However,
the inheritance of the G allele at IL-10 -1082 may favor
concurrent autoimmunity in DTC with lymphocyte recruit-
ment and hence modulate an antitumor immune reaction.
Further studies are needed to confirm the hypothesis of
tumor cell depletion by immune cells and to elucidate the
mechanisms engaged in this process.
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